LRRK2 and colitis: However, MLi-2 had minimal impact on body weight loss, spleen weight, and colon length, damage, and inflammation, suggesting that in-diet dosing of the LRRK2 kinase inhibitor MLi-2 does not provide significant protection from DSS-induced colitis in N2081D mutation carriers (Supplemental Figure 7, E–I).